SUPLEXA, a multimodal autologous cellular therapy, shows immunomodulatory behavior in cancer patients consistent with improved anti-tumor immune function

Conclusions:

• Phase 1 clinical outcomes indicate; 1) pristine safety in all 28 end-stage cancer patients treated with SUPLEXA cells, 2) Complete or partial responses in MSI-Hcolorectal cancer patients and stable disease in renal cell carcinoma and melanoma patients.
• Immunomodulation of blood activated classical monocytes and PMN-MDSCs in CRC patients showing beneficial clinical responses to SUPLEXA therapeutic cells.
• Circulating cytokines and biomarkers are significantly modulated by SUPLEXA cell treatments.